King's College London

Research portal

FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study

Research output: Contribution to journalArticle

Standard

FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. / Mikhaeel, N. George; Cunningham, David; Counsell, Nicholas; McMillan, Andrew; Radford, John A.; Ardeshna, Kirit M.; Lawrie, Anthony; Smith, Paul; Clifton-Hadley, Laura; O'Doherty, Michael J.; Barrington, Sally F.

In: British Journal of Haematology, 01.01.2020.

Research output: Contribution to journalArticle

Harvard

Mikhaeel, NG, Cunningham, D, Counsell, N, McMillan, A, Radford, JA, Ardeshna, KM, Lawrie, A, Smith, P, Clifton-Hadley, L, O'Doherty, MJ & Barrington, SF 2020, 'FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study', British Journal of Haematology. https://doi.org/10.1111/bjh.16875

APA

Mikhaeel, N. G., Cunningham, D., Counsell, N., McMillan, A., Radford, J. A., Ardeshna, K. M., Lawrie, A., Smith, P., Clifton-Hadley, L., O'Doherty, M. J., & Barrington, S. F. (Accepted/In press). FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. British Journal of Haematology. https://doi.org/10.1111/bjh.16875

Vancouver

Mikhaeel NG, Cunningham D, Counsell N, McMillan A, Radford JA, Ardeshna KM et al. FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. British Journal of Haematology. 2020 Jan 1. https://doi.org/10.1111/bjh.16875

Author

Mikhaeel, N. George ; Cunningham, David ; Counsell, Nicholas ; McMillan, Andrew ; Radford, John A. ; Ardeshna, Kirit M. ; Lawrie, Anthony ; Smith, Paul ; Clifton-Hadley, Laura ; O'Doherty, Michael J. ; Barrington, Sally F. / FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study. In: British Journal of Haematology. 2020.

Bibtex Download

@article{09b73cc6051d4631887d10072ea87579,
title = "FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study",
abstract = "The UK National Cancer Research Institute initiated a prospective study (UKCRN-ID 1760) to assess the prognostic value of early fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in diffuse large B-cell lymphoma (DLBCL). In total, 189 patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) had baseline and post-cycle-2 PET (PET2) within a quality assurance framework. Treatment decisions were based on CT; PET2 was archived for central blinded reporting after treatment completion. The association of PET2 response with end-of-treatment CT, progression-free (PFS) and overall survival (OS) was explored. The end-of-treatment complete response rate on CT was 83·9%, 75·0%, 70·5%, 40·4% and 36·4% for Deauville score (DS) 1 (n = 34), 2 (n = 39), 3 (n = 46), 4 (n = 56) and 5 (n = 14) (P < 0·001); and 64·1% and 50·0% for the maximum standardised uptake value (∆SUVmax) of ≥66% (n = 168) and <66% (n = 21), respectively (P = 0·25). After a median 5·4 years of follow-up, the 5-year PFS was 69·4%, 72·8%, 76·7%, 71·2% and 47·6% by DS 1–5 (P = 0·01); and 72·6% and 57·1% by ∆SUVmaxof ≥66% and <66% (P = 0·03), respectively. The association with DS remained in multivariable analyses, and was consistent for OS. Early complete metabolic response (DS 1–3) at interim PET/CT after two cycles of R-CHOP in DLBCL was associated with a higher end-of-treatment complete and overall response rate; however, only DS-5 patients had inferior PFS and OS.",
keywords = "diffuse large B-cell lymphoma (DLBCL), positron emission tomography (PET), R-CHOP chemotherapy",
author = "Mikhaeel, {N. George} and David Cunningham and Nicholas Counsell and Andrew McMillan and Radford, {John A.} and Ardeshna, {Kirit M.} and Anthony Lawrie and Paul Smith and Laura Clifton-Hadley and O'Doherty, {Michael J.} and Barrington, {Sally F.}",
year = "2020",
month = jan,
day = "1",
doi = "10.1111/bjh.16875",
language = "English",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell Publishing Ltd",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome – final result of a UK National Cancer Research Institute prospective study

AU - Mikhaeel, N. George

AU - Cunningham, David

AU - Counsell, Nicholas

AU - McMillan, Andrew

AU - Radford, John A.

AU - Ardeshna, Kirit M.

AU - Lawrie, Anthony

AU - Smith, Paul

AU - Clifton-Hadley, Laura

AU - O'Doherty, Michael J.

AU - Barrington, Sally F.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The UK National Cancer Research Institute initiated a prospective study (UKCRN-ID 1760) to assess the prognostic value of early fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in diffuse large B-cell lymphoma (DLBCL). In total, 189 patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) had baseline and post-cycle-2 PET (PET2) within a quality assurance framework. Treatment decisions were based on CT; PET2 was archived for central blinded reporting after treatment completion. The association of PET2 response with end-of-treatment CT, progression-free (PFS) and overall survival (OS) was explored. The end-of-treatment complete response rate on CT was 83·9%, 75·0%, 70·5%, 40·4% and 36·4% for Deauville score (DS) 1 (n = 34), 2 (n = 39), 3 (n = 46), 4 (n = 56) and 5 (n = 14) (P < 0·001); and 64·1% and 50·0% for the maximum standardised uptake value (∆SUVmax) of ≥66% (n = 168) and <66% (n = 21), respectively (P = 0·25). After a median 5·4 years of follow-up, the 5-year PFS was 69·4%, 72·8%, 76·7%, 71·2% and 47·6% by DS 1–5 (P = 0·01); and 72·6% and 57·1% by ∆SUVmaxof ≥66% and <66% (P = 0·03), respectively. The association with DS remained in multivariable analyses, and was consistent for OS. Early complete metabolic response (DS 1–3) at interim PET/CT after two cycles of R-CHOP in DLBCL was associated with a higher end-of-treatment complete and overall response rate; however, only DS-5 patients had inferior PFS and OS.

AB - The UK National Cancer Research Institute initiated a prospective study (UKCRN-ID 1760) to assess the prognostic value of early fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) in diffuse large B-cell lymphoma (DLBCL). In total, 189 patients with DLBCL treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) had baseline and post-cycle-2 PET (PET2) within a quality assurance framework. Treatment decisions were based on CT; PET2 was archived for central blinded reporting after treatment completion. The association of PET2 response with end-of-treatment CT, progression-free (PFS) and overall survival (OS) was explored. The end-of-treatment complete response rate on CT was 83·9%, 75·0%, 70·5%, 40·4% and 36·4% for Deauville score (DS) 1 (n = 34), 2 (n = 39), 3 (n = 46), 4 (n = 56) and 5 (n = 14) (P < 0·001); and 64·1% and 50·0% for the maximum standardised uptake value (∆SUVmax) of ≥66% (n = 168) and <66% (n = 21), respectively (P = 0·25). After a median 5·4 years of follow-up, the 5-year PFS was 69·4%, 72·8%, 76·7%, 71·2% and 47·6% by DS 1–5 (P = 0·01); and 72·6% and 57·1% by ∆SUVmaxof ≥66% and <66% (P = 0·03), respectively. The association with DS remained in multivariable analyses, and was consistent for OS. Early complete metabolic response (DS 1–3) at interim PET/CT after two cycles of R-CHOP in DLBCL was associated with a higher end-of-treatment complete and overall response rate; however, only DS-5 patients had inferior PFS and OS.

KW - diffuse large B-cell lymphoma (DLBCL)

KW - positron emission tomography (PET)

KW - R-CHOP chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85087465042&partnerID=8YFLogxK

U2 - 10.1111/bjh.16875

DO - 10.1111/bjh.16875

M3 - Article

AN - SCOPUS:85087465042

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454